A.T.S. Pharmaceuticals, A Division of Auriga Laboratories, Inc. Launches Xyralid(TM) RC
Published: Jul 09, 2007
LOS ANGELES--(BUSINESS WIRE)--Auriga Laboratories, Inc. (OTCBB:ARGA), a specialty pharmaceutical company with products for the treatment of acute respiratory diseases, dermatological conditions, and xerostomia, announced today the launch of Xyralid™ RC (lidocaine HCL 3%/hydrocortisone acetate 1%) rectal cream kit, a convenience kit that contains a seven- day supply (14 units) of Xyralid Rectal Cream and a 7 day supply of Konsyl® Natural Bulk-Forming Laxative with a convenient shaker cup. Xyralid RC will be promoted to Gastroenterologists and Colon Rectal Specialists by the recently announced 46-person ATS Pharmaceutical division of Auriga. According to Wolters Kluwer Health, Inc., the overall US hemorrhoid prescription market exceeds $88 million annually. The American Society of Colon & Rectal Surgeons (ASCRS) recommends increasing the amount of fiber and fluids in the diet to relieve mild hemorrhoid symptoms1.